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ScienceDirectVesicular trafficking is critical for the function of bone cells,
exemplified by bone diseases such as osteopetrosis, which
frequently results from defects in this process. Recent work has
further dissected the role of the endolysosomal system in both
bone formation by osteoblasts and bone resorption by
osteoclasts. This pathway also plays an important role in the
communication between these and other cells in bone, through
trafficking and degradation of growth factors and their
receptors, and microvesicle release. In addition, a crucial role
for autophagy in bone remodelling and bone disease is
beginning to emerge. These insights into the molecular control
of bone remodelling raise the possibility of developing novel
therapeutics for bone diseases designed to target specific
aspects of this process.
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Introduction
Vesicular trafficking is at the basis of cellular life; it
governs cell communication via secretion and uptake of
signalling molecules, enzymes and adhesion molecules.
Furthermore, the identity of intracellular organelles is
dependent on vesicular trafficking. Seminal work by
Rothman, Schekman and others beginning in the 1980s
has led to the elucidation of the mechanisms underlying
vesicular transport [1]. Vesicles bud from the membrane
of a donor compartment (e.g. the trans-Golgi network)
and are subsequently transported to a different, destina-
tion compartment (e.g. the plasma membrane), where
Open access under CC BY license.www.sciencedirect.com membrane fusion occurs. Vesicular budding at the donor
membrane is controlled by small GTPases mainly
belonging to the ADP ribosylation factor (ARF) family
[2]. ARFs recruit coat proteins, which select cargo
proteins and shape the membrane into a bud [3]. At
the target membrane, vesicles dock and cargo is delivered
through membrane fusion, mediated by small membrane
proteins associated with the vesicular membrane (v-
SNARE) and the target membrane (t-SNARE) [4]. In
addition to these proteins, the Rab family of small
GTPases are master regulators of vesicular trafficking,
with important roles in cargo selection, vesicle budding,
cytoskeletal transport, and docking at the target mem-
brane [5,6].
In bone, certain diseases have highlighted the importance
of vesicular trafficking in bone cells. For example, most
autosomal recessive cases of the bone disease osteope-
trosis result from defects in endolysosomal trafficking in
osteoclasts (Box 1; [7]). In osteoblasts, mutations in genes
that regulate ER to Golgi traffic account for the skeletal
defect in observed in patients with cranio-lenticulo-
sutural dysplasia [8] and gerodermia osteodysplastica
[9]. In addition, genetic disruption of post-translational
modification of Rab GTPases impairs both osteoblast and
osteoclast function [10].
Osteoblasts
Transport from the ER and ER stress in osteoblasts
Patients with cranio-lenticulo-sutural dysplasia have a
mutation in one of the COPII coat subunits (sec23A)
that regulates budding of collagen-containing vesicles
from the endoplasmic reticulum [8]. Fibroblasts from
patients with cranio-lenticulo-sutural dysplasia show an
extended ER and reduced collagen production. A similar
picture is observed in fibroblasts from mice lacking
BBF2H7 (box B-binding factor-2 human homolog on
chromosome 7). BBF2H7 belongs to a family of ER
localised transmembrane transcription factors that are
transported to the Golgi complex under ER stress [11].
In the Golgi, cleavage by the Golgi resident proteases S1P
(site-1 protease) and S2P (site-2 protease) also known as
SKI-1 (subtilisin kexin isozyme-1 and 2) liberates the N-
terminal basic leuzine zipper transcription factor domain
that then translocates to the nucleus (Figure 1). BBF2H7
is highly expressed in chondrocytes and sec23A is a
transcriptional target of BBF2H7, explaining the similar
phenotype observed in cranio-lenticulo-sutural dysplasia
and BBF2H7/ mice. BBF2H7 is not expressed in
osteoblasts but ER stress activates a similar system,
involving OASIS (old astrocyte specifically induced sub-
stance) [12]. OASIS gene transcription is induced by boneCurrent Opinion in Pharmacology 2014, 16:7–14
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Box 1 Vesicular trafficking defects in osteopetrosis
The genetic bone disease osteopetrosis is associated with high bone
density due to defective resorption by osteoclasts. Over recent years
it has become clear that the mutations that cause osteoclast-rich
osteopetrosis (i.e. in which osteoclasts form normally, but their
resorptive activity is impaired) all impair trafficking and/or fusion of
lysosome-related organelles to the ruffled border [7]. The most
common osteopetrosis-causing mutations are in the a3 subunit of
the V-ATPase and the two subunits of the ClC-7 chloride antiporter,
suggesting that the osteoclast defect in these cases results from
impaired lysosomal acidification. However, osteoclasts from patients
bearing these mutations completely lack ruffled borders, indicative of
a defect in lysosomal trafficking. More recently, truncating mutations
in Plekhm1 have been identified as a cause of osteopetrosis, with an
identical osteoclast phenotype in vitro to the a3 and ClC-7
mutations. Plekhm1 is recruited to cathepsin K-positive lysosomes in
osteoclasts by GTP-bound Rab7, and is therefore likely to be a Rab7
effector; the mutant form of Plekhm1 cannot be recruited to these
vesicles and remains cytoplasmic. Finally, mutations in sorting nexin
10 (SNX10) also cause osteopetrosis. Although the function of
SNX10 in osteoclasts remains unclear, SNX proteins are known to
function in endosomal sorting and signalling, thus linking these cases
mechanistically to the other causes of osteopetrosis [69].
Current Opinion in Pharmacology 2014, 16:7–14 morphogenetic protein 2 (BMP2) downstream of Runx2
activation [13] and collagen type I is a direct transcriptional
target of OASIS. The importance of OASIS and ER stress
in bone formation is further highlighted by the phenotype
of OASIS/mice that suffer from severe osteopenia akin
to human osteogenesis imperfecta (OI) [13].
ER stress is induced by a number of factors such as ER-
calcium depletion, oxidative stress, hypoglycaemia and
expression of mutated proteins [14]. However, in chon-
drocytes and osteoblasts this system is activated by
differentiation and involves BBF2H7 and OASIS respect-
ively. Interestingly, expression of the ER chaperone BIP
(immunoglobulin heavy-chain binding protein) is
reduced in osteoblasts of osteoporosis patients and a
selective inducer of BIP prevents bone loss in a murine
osteoporosis model [15], indicating that regulation of ER
stress plays an important role in bone formation.
Activation of transcription factors by transport from the ER
to the Golgi was first described for SREBP (Sterol-Regu-
latory Element-Binding Protein), whose translocation4
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involving the COPII coat (for review see [16]). It will be
interesting to see if similar interactions between OASIS
and other ER resident proteins facilitate COPII coat
binding and are involved in collagen secretion in osteo-
blasts.
RANKL and collagen secretion
The endosomal/lysosomal compartments of cells are very
plastic, receiving material from both the extracellular
environment via endocytosis as well as newly synthesised
material for regulated exocytosis. The endosome/lyso-
some thus functions as both a degradative and a secretory
compartment. In osteoblasts the secretory function of this
compartment appears to be important for the secretion of
both receptor activator for NF-kB-ligand (RANKL) and
collagen.
RANKL is the most important factor in the crosstalk
between cells of the osteoblast lineage and osteoclasts,
and the ratio between RANKL and osteoprotegerin (OPG)
is crucial for bone homeostasis. RANKL is secreted/pre-
sented by osteoblastic cells and the interaction between
RANKL and its receptor RANK on pre-osteoclasts initiates
osteoclast differentiation and maturation. OPG has been
identified as a decoy receptor for RANKL thereby redu-
cing the amount of RANKL available for stimulation of
pre-osteoblasts. Interestingly, in osteoblasts and osteocytes
the majority of RANKL is not directly routed from the
Golgi apparatus to the plasma membrane but is stored
before secretion in a lysosomal compartment [17,18]
(Figure 1). Trafficking to the lysosomes is dependent on
OPG, which then maintains RANKL in this compartment
until secretion is promoted by RANK/RANKL interaction
at the plasma membrane [17]. Therefore regulation of bone
remodelling by OPG occurs through modulation of intra-
cellular trafficking as well as extracellular binding of
RANKL.
The importance of secretory lysosomes in bone homeo-
stasis has been highlighted by the bone phenotype (osteo-
penia/increased bone volume respectively) of two mouse
strains, synaptotagmin VII/ and jinx (loss of function
mutation in Munc 13-4) mice [19,20]. Both synaptotag-
min VII and Munc 13-4 are components of the docking
and fusion machinery necessary for lysosome and multi-
vesicular body (MVB) secretion. Munc 13-4 is an effector
of Rab27, a small GTPase that regulates secretory lyso-
some release [21], whereas synaptotagmin VII modulates
the fusion event itself [22]. The differences in the mouse
phenotypes are likely due to the specific functions these
proteins play in osteoblasts and osteoclasts. The role of
Rab27 appears to be restricted to osteoblasts, where it
may regulate plasma membrane expression of RANKL
[19], which could explain the jinx mouse phenotype.
Rab27 also appears to regulate collagen secretion most
likely through a Munc 13-4-independent mechanismwww.sciencedirect.com [23]. By contrast synaptotagmin VII is essential for both
osteoblast and osteoclast function, due to the requirement
for lysosome secretion in both these cell types [20]. In
osteoclasts, trafficking of these lysosomes is under the
control of Rab7 rather than Rab27.
Microvesicle release
Endosomes mature into lysosomes via MVBs, which
contain numerous small intra-luminal vesicles [24].
Similar to lysosomes, under certain circumstances MVBs
can fuse with the plasma membrane, resulting in the
extracellular release of these 40–100 nm microvesicles,
which are then termed exosomes. Alternatively, micro-
vesicles can form directly from the plasma membrane [25]
(Figure 1). In osteoblasts, a type of microvesicle known as
a matrix vesicle is crucial for mineralisation of bone [26]
and the release of intracellular calcium [27]. The import-
ance of the actin cytoskeleton in matrix vesicle release has
recently been highlighted by several studies [28,29]. In
recent years it has become clear that microvesicles are also
important for cell to cell communication, as they contain
RNAs, including microRNAs, DNA and enzymes [30].
They can act locally or at distant sites as they are released
into body fluids, such as blood, saliva and urine. At target
cells they bind to receptors or are taken up by endocy-
tosis, the released components then altering gene expres-
sion. Furthermore, microvesicles can also release
nucleotides, which work as autocrine/paracrine signalling
molecules via purinergic receptors [31] and the purinergic
P2X7 receptor itself has been shown to induce micro-
vesicle shedding in a number of cell types [32]. In bone, it
has recently been shown that monocytes use exosomes to
stimulate osteogenic gene expression in mesenchymal
stem cells [33]. Importantly, bone marrow-mesenchymal
stem cells (BM-MSC) communicate with multiple myel-
oma (MM) cells via exosomes; exosomes derived from
normal BM-MSC inhibit the growth of MM cells whereas
MM BM-MSC derived exosomes promote it [34].
Endocytosis regulates differential signalling in
osteoblasts
Steady state levels of a number of proteins, especially
cytokine and growth factor receptors, are controlled by
selective internalisation. Endocytosed proteins first reach
the endosome where cargo sorting takes place; interna-
lised proteins may then recycle back to the plasma
membrane or are delivered to the lysosome for degra-
dation (Figure 1). This selective internalisation fine-tunes
receptor signalling [35]. A striking example of this mech-
anism is the parathyroid hormone/parathyroid hormone
related protein (PTH/PTHrP) receptor type I (PTH1R).
PTH regulates whole body calcium homeostasis whereas
PTHrP is a paracrine factor that has an anabolic effect on
bone by controlling osteoblast differentiation and pro-
liferation. Both proteins bind to the same receptor
(PTH1R) but elicit different responses. PTH binding
to the receptor triggers endocytosis and a sustained cAMPCurrent Opinion in Pharmacology 2014, 16:7–14
10 Musculoskeletalproduction whereas PTHrP rapidly dissociates from the
receptor so that only a transient cAMP increase is induced
at the plasma membrane [36]. The two ligands thus
stabilise different conformations of the receptor leading
to changes in signal strength, which is dependent on
receptor endocytosis and sustained signalling on the
endosome. This extended signalling after internalisation
might explain why bone anabolic effects are seen with
intermittent PTH treatment only, whereas continued
PTH treatment results in bone loss [37,38]. Another
example of signal modulation by selective internalisation
is the recently described interaction between transform-
ing growth factor (TGF)-b type II receptor and PTH1R.
TGF-b is a local factor deposited in the bone matrix that
plays an important role in bone maintenance [39]. It is
activated by bone resorbing osteoclasts and attenuates
further bone resorption by impairing osteoclastogenesis.
TGF-b promotes bone formation through chemotactic
attraction of osteoblasts and their precursors, whose pro-
liferation and differentiation is stimulated. TGF-b inter-
acts with a large number other growth factors and
hormones, one of which is PTH. In response to PTH,
PTH1R forms a complex with TGF-b type II receptor,
one of the three TGF-b receptors. Subsequent phos-
phorylation of PTH1R by the constitutively active
TGF-b type II receptor triggers formation of an endocytic
complex [40]. Both receptors are removed from the
plasma membrane and signalling is attenuated. Inter-
action between PTH1R and TGF-b type II receptor is
reduced by TGF-b binding to its receptor so that endo-
cytosis rates modulate signalling strength of both path-
ways.
Osteoclasts
Vesicular trafficking to the ruffled border
Here we focus on vesicular trafficking to the ruffled
border, the resorptive organelle of the osteoclast; other
trafficking routes in osteoclasts have been reviewed else-
where [41,42]. The ruffled border forms as a result of
extensive vesicular fusion within the area bounded by the
actin-rich sealing zone, where the osteoclast adheres to
the bone matrix (Figure 2). This process creates a huge
surface area for the continuing delivery of acid and
proteases responsible for degrading type I collagen, prin-
cipally cathepsin K, to the resorption lacuna. Trafficking
to this domain occurs through at least two independent
pathways, a Rab7-regulated lysosomal pathway and a
Rab3D-regulated non-lysosomal pathway [41]
(Figure 2). An effector of Rab7 in osteoclasts, Plekhm1,
is recruited to the secretory lysosomes by Rab7 and plays
a crucial role in their trafficking to the ruffled border [43].
The function of this protein appears to be largely
restricted to osteoclasts, since mutations in the gene
encoding this protein are responsible for rare cases of
osteopetrosis (see Box 1). Rab3D, which is known to
regulate exocytosis in cells with high secretory require-
ments, localises to a subpopulation of post-TGN vesiclesCurrent Opinion in Pharmacology 2014, 16:7–14 in osteoclasts, rather than lysosomes, and appears to
regulate the trafficking of these vesicles to the ruffled
border [44].
Both these types of vesicles are trafficked to the plus end
of microtubules at the ruffled border, that is, the same
orientation as the plasma membrane of other cell types
[45]. However, it has become apparent that the dynein–
dynactin motor complex, which regulates trafficking of
vesicles towards microtubule minus ends, is essential for
targeting of both vesicular populations to the ruffled
border. Tctex-1, one of many different light chains of
the dynein complex, interacts with GTP-bound Rab3D,
and RNA interference studies have implicated it in the
trafficking of Rab3D-containing vesicles in osteoclasts
[46]. In addition, trafficking of cathepsin K-containing
lysosomes to the RB is prevented by disruption of the
dynein–dynactin complex, presumably involving a differ-
ent dynein light chain that has yet to be identified [45].
The dynein motor adapter Lissencephaly-1 (LIS1) plays
a role in this process; LIS1 binds to dynein in osteoclasts
and also interacts with Plekhm1 [47], thereby potentially
linking the dynein motor to lysosomes via Plekhm1 and
Rab7 in osteoclasts, shedding light on the role of Plekhm1
in lysosomal trafficking (Figure 2, inset). Decreasing LIS1
expression causes perinuclear accumulation of lysosomes,
and impairs cathepsin K secretion [47]. Although it seems
counterintuitive that a minus-end motor is essential for
trafficking to the plus-end ruffled border, dynein is known
to be able to act as a molecular anchor at the plus ends of
microtubules [48], and may therefore tether secretory
lysosomes here before membrane fusion [45].
The signalling pathways that stimulate secretion of lyso-
somes in osteoclasts are not well understood. However, it
has recently been demonstrated that osteoclast-specific
impairment of the class IA phosphatidylinositide 3-kinase
(PI3K) by deletion of the p85 regulatory subunit results in
an osteopetrotic (high bone mass) phenotype due to
defective ruffled border formation and secretion of cath-
epsin K [49]. The sealing zone remains intact, supporting
a direct role in lysosomal trafficking, most likely through
activation of Akt [49]. Moreover, an isoform of protein
kinase C that is highly expressed in osteoclasts, PKCd,
also plays a role in lysosomal trafficking [50]. PKCd
phosphorylates the actin bundling protein MARCKS,
displacing it from the membrane and impairing its actin
binding ability, resulting in a local loss of actin filaments,
which enables fusion of cathepsin K-containing lyso-
somes at the membrane [51]. Interestingly, trafficking
of the V-ATPase and formation of the ruffled border are
unaffected by PKCd deficiency, suggesting that cathepsin
K and the V-ATPase may reach the ruffled border through
distinct trafficking mechanisms [51], which could also
include polarised mRNA transport [52,53]. In support of
this model, cathepsin K has been localised to F-actin free
regions of the ruffled border, distinct from those occupiedwww.sciencedirect.com
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Schematic overview of trafficking pathways to the ruffled border in osteoclasts. Cathepsin K is trafficked in ‘secretory lysosomes’, whereas V-ATPase
can also traffic to the ruffled border through an independent pathway, most likely a cathepsin D-positive lysosomal compartment, but also the Rab3D-
positive ‘secretory vesicles’. Both secretory lysosomes and secretory vesicles are trafficked on the microtubules towards plus ends at the ruffled
border (inset). The dynein motor complex is crucial for this process, possibly by tethering the cargo at the plus ends before fusion. The molecular
interactions here, however, are different; for rab3D-expressing vesicles involving the dynein light chain Tctex1, and for Rab7-expressing lysosomes the
adapter LIS1, possibly through binding to Plekhm1 (inset). Fusion at the ruffled border is poorly understood, but in the case of the lysosomal
compartment involves synaptotagmin VII and most likely LC3.by the V-ATPase [54]. Furthermore, disruption of dynein
does not impair acidification of the resorption lacuna [45]
suggesting that it is not involved in V-ATPase trafficking.
Further support for the existence of two distinct lysoso-
mal subpopulations in osteoclasts is provided by a mouse
model with defects in the mannose-6-phosphate targeting
pathway [55]. Secretory lysosomes containing cathepsin K
and TRAP are dependent on the conventional mannose-
6-phosphate targeting pathway, whereas a distinct popu-
lation of cathepsin D-positive lysosomes are formed
through a mannose-6-phosphate-independent pathway
and likely carry out general lysosomal functions within
the osteoclast [55]. However, it is possible that these
vesicles may also fuse with the plasma membrane (andwww.sciencedirect.com potentially also with secretory lysosomes), which could
represent the means by which V-ATPase is able to traffic
to the RB independently of cathepsin K, although cath-
epsin D has not been shown to localise to the ruffled
border [51]. In mannose-6-phosphate defective osteo-
clasts, cathepsin K is mistargeted and constitutively
secreted from the TGN; this trafficking route is likely
to be the Rab3D-regulated pathway that has been shown
to be important for RB formation [45], although evidence
for this is currently lacking.
Autophagy and bone
Autophagy is the vesicular trafficking process by which
cells degrade and recycle misfolded proteins/damaged
organelles; this recycling process is also crucial for survivalCurrent Opinion in Pharmacology 2014, 16:7–14
12 Musculoskeletalunder stressful conditions such as nutrient starvation [56].
It begins with de novo formation of double-membraned
autophagosomes around the cargo selected for degra-
dation, which then fuse with lysosomes to form the
autolysosome, thereby enabling degradation of cargo to
occur. The importance of autophagy in bone cells is only
just becoming clear. Autophagy-related proteins, in-
cluding lipidated Atg8/LC3 (which is frequently used
as a marker of autophagy), are essential for bone resorp-
tion by osteoclasts, but this may be through a non-autop-
hagic role for LC3 in controlling the fusion of secretory
lysosomes at the ruffled border [57] (Figure 2). This
would help to explain the finding that levels of lipidated
LC3 increase during differentiation, apparently indepen-
dently from levels of autophagy [58]. In support of this, it
has recently become clear that autophagy-related proteins
possess a range of non-autophagic roles in many other cell
types, including participation in exocytotic processes [59].
In addition, it has been suggested that the pathogenesis of
Paget’s disease of bone (PBD) may be at least partly due
to alterations in autophagy. PDB is a late-onset disorder
characterised by focal areas of increased bone turnover
containing enlarged, hyperactive osteoclasts. The disease
has a strong genetic predisposition and has been associ-
ated with mutations in the ubiquitin-binding domain of
p62 (SQSTM1), a protein that plays a crucial role in the
recruitment to autophagosomes of material to be
degraded. These mutations result in the formation of
intracellular aggregates that are clearly visible by electron
microscopy, possibly due to defective autophagic clear-
ance. However, how such disturbances may contribute to
the pathogenesis of the disease remain unclear [60].
Furthermore, defects in autophagy have been detected
in a mouse model of a disease with a similar bone
phenotype, inclusion body myopathy associated with
PDB and frontotemporal dementia (IBMPFD), which
is caused by mutations in valosin-containing protein
(VCP). However, osteoclasts from these mice have yet
to be studied [61].
Recent work has linked the age-related decline in bone
mass to alterations in autophagy in osteocytes [62].
Impairment of autophagy in osteocytes by conditional
deletion of the autophagy gene Atg7 decreased bone mass
in 6-month-old mice. This was associated with decreased
osteoclast and osteoblast number, reduced bone for-
mation rate, and increased oxidative stress, alterations
that are all characteristic of changes in ageing mice. The
mechanism underlying these changes remains unclear,
but this raises the possibility that stimulating autophagy
in osteocytes may be able to reverse age-related bone loss.
Vesicle trafficking pathways as
pharmacological targets
Bisphosphonates, which are currently the most widely
used class of drugs for the treatment of osteoporosis andCurrent Opinion in Pharmacology 2014, 16:7–14 other disease associated with excessive bone resorption,
disrupt osteoclast-mediated bone resorption by inhibiting
the function of Rab GTPases, thereby impairing vesicular
trafficking, as well as impairing other small GTPase-de-
pendent processes [63]. Interestingly, bisphosphonates
may have additional effects on vesicular trafficking in
osteoblasts. In Oasis/ mice, which are characterised by
osteopenia due to defective type I collagen secretion,
bisphosphonates inhibit osteoclastic resorption and the
resulting low bone turnover reduces osteoblastic ER
expansion contributing to the observed increase in bone
volume [64]. Modulators of ER stress themselves have
shown potential as treatment options in osteoporosis [15].
The highly osteoclast-specific nature of osteopetrosis-
causing mutations has identified the proteins encoded
by these genes as promising novel anti-resorptive targets.
One potential advantage of this approach is that it would
result in increased numbers of inactive osteoclasts, and
consequently increased bone formation as a result of the
coupling process, whereby osteoclasts (active or inactive)
are able to promote the activity of osteoblasts [65]. Other
potential targets include the class IA PI3K, which plays a
role in formation of the ruffled border. Established inhibi-
tors of the p100b and p100d catalytic subunits of this
enzyme, TGX-221 and GS-9820, respectively, have
recently been shown to inhibit osteoclast activity in vitro,
but with differing effects on cytoskeletal organisation
[66].
Finally, microvesicles have therapeutic relevance as they
have been shown to not only be of prognostic value but
have potential as gene therapeutic and drug delivery tools
[67]. Furthermore, they might hold the clue to the osteo-
clast derived coupling factor that regulates osteoblast
activity possibly through the stimulation of canopy cells
that are situated above the osteoclast in vivo [68].
In conclusion, significant advances in our understanding
of the role of vesicular trafficking in bone homeostasis
have been made in recent years, identifying a plethora of
possible drug targets. It remains to be seen how many
novel drugs that target these pathways are ultimately
translated into clinical use for bone diseases.
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